(R)-2-(3-chloro-4-(methylsulfonyl)phenyl)-3-((R)-3-oxocyclopentyl)-N-(pyrazin-2-yl)propanamide

ID: ALA1783734

Chembl Id: CHEMBL1783734

Cas Number: 625114-41-2

PubChem CID: 10432339

Max Phase: Phase

Molecular Formula: C19H20ClN3O4S

Molecular Weight: 421.91

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Synonyms: R04389620 | R04389620\ | RO-4389620 | RO4389620-R1440 | Piragliatin|625114-41-2|UNII-BM1HR7IP1L|BM1HR7IP1L|Piragliatin [USAN:INN]|RO4389620|Piragliatin [USAN]|RO4389620-R1440|Ro 4389620|(2R)-2-(3-chloro-4-methylsulfonylphenyl)-3-[(1R)-3-oxocyclopentyl]-N-pyrazin-2-ylpropanamide|CHEMBL1783734|DTXSID3048520|RO-4389620|Piragliatin (USAN)|R-1440|R04389620\\|R 1440|(2R)-2-(3-Chloro-4-(methylsulfonyl)phenyl)-3-((1R)-3-oxocyclopentyl)-N-pyrazinylpropanamide|(2r)-2-[3-Chloro-4-(Methylsulfonyl)phenyl]-3-Show More

Canonical SMILES:  CS(=O)(=O)c1ccc([C@@H](C[C@H]2CCC(=O)C2)C(=O)Nc2cnccn2)cc1Cl

Standard InChI:  InChI=1S/C19H20ClN3O4S/c1-28(26,27)17-5-3-13(10-16(17)20)15(9-12-2-4-14(24)8-12)19(25)23-18-11-21-6-7-22-18/h3,5-7,10-12,15H,2,4,8-9H2,1H3,(H,22,23,25)/t12-,15+/m0/s1

Standard InChI Key:  XEANIURBPHCHMG-SWLSCSKDSA-N

Alternative Forms

  1. Parent:

    ALA1783734

    PIRAGLIATIN

Associated Targets(Human)

GCK Tchem Hexokinase type IV (3191 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver microsomes (16955 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasma (7708 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hepatocyte (2737 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Caco-2 (12174 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver microsomes (8692 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Canis familiaris (36305 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasma (280 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasma (810 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasma (10718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasma (6361 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rhesus monkey (3147 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver (618 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver (8163 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Gck Hexokinase type IV (278 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: YesOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: YesAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 421.91Molecular Weight (Monoisotopic): 421.0863AlogP: 3.02#Rotatable Bonds: 6
Polar Surface Area: 106.09Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 11.19CX Basic pKa: 0.08CX LogP: 1.61CX LogD: 1.61
Aromatic Rings: 2Heavy Atoms: 28QED Weighted: 0.77Np Likeness Score: -0.87

References

1. Pfefferkorn JA, Lou J, Minich ML, Filipski KJ, He M, Zhou R, Ahmed S, Benbow J, Perez AG, Tu M, Litchfield J, Sharma R, Metzler K, Bourbonais F, Huang C, Beebe DA, Oates PJ..  (2009)  Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle.,  19  (12): [PMID:19435665] [10.1016/j.bmcl.2009.04.107]
2. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 
3. Sarabu R, Bizzarro FT, Corbett WL, Dvorozniak MT, Geng W, Grippo JF, Haynes NE, Hutchings S, Garofalo L, Guertin KR, Hilliard DW, Kabat M, Kester RF, Ka W, Liang Z, Mahaney PE, Marcus L, Matschinsky FM, Moore D, Racha J, Radinov R, Ren Y, Qi L, Pignatello M, Spence CL, Steele T, Tengi J, Grimsby J..  (2012)  Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.,  55  (16): [PMID:22809456] [10.1021/jm3008689]
4. Sarabu R, Bizzarro FT, Corbett WL, Dvorozniak MT, Geng W, Grippo JF, Haynes NE, Hutchings S, Garofalo L, Guertin KR, Hilliard DW, Kabat M, Kester RF, Ka W, Liang Z, Mahaney PE, Marcus L, Matschinsky FM, Moore D, Racha J, Radinov R, Ren Y, Qi L, Pignatello M, Spence CL, Steele T, Tengi J, Grimsby J..  (2012)  Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.,  55  (16): [PMID:22809456] [10.1021/jm3008689]
5. Qian Y, Corbett WL, Berthel SJ, Choi DS, Dvorozniak MT, Geng W, Gillespie P, Guertin KR, Haynes NE, Kester RF, Mennona FA, Moore D, Racha J, Radinov R, Sarabu R, Scott NR, Grimsby J, Mallalieu NL..  (2013)  Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes.,  (4): [PMID:24900686] [10.1021/ml400027y]
6. PubChem BioAssay data set, 
7. Pfefferkorn JA, Guzman-Perez A, Oates PJ, Litchfield J, Aspnes G, Basak A, Benbow J, Berliner MA, Bian J, Choi C, Freeman-Cook K, Corbett JW, Didiuk M, Dunetz JR, Filipski KJ, Hungerford WM, Jones CS, Karki K, Ling A, Li J, Patel L, Perreault C, Risley H, Saenz J, Song W, Tu M, Aiello R, Atkinson K, Barucci N, Beebe D, Bourassa P, Bourbounais F, Brodeur AM, Burbey R, Chen J, D'Aquila T, Derksen DR, Haddish-Berhane N, Huang C, Landro J, Lee Lapworth A, MacDougall M, Perregaux D, Pettersen J, Robertson A, Tan B, Treadway JL, Liu S, Qiu X, Knafels J, Ammirati M, Song X, DaSilva-Jardine P, Liras S, Sweet L, Rolph TP.  (2011)  Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus,  (9): [10.1039/C1MD00116G]
8. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]
9. Borzilleri KA, Pfefferkorn JA, Guzman-Perez A, Liu S, Qiu X, Chrunyk BA, Song X, Tu M, Filipski KJ, Aiello R, Derksen DR, Bourbonais FJ, Landro J, Bourassa P, D'Aquila T, Baker L, Barrucci N, Litchfield J, Atkinson K, Rolph TP, Withka JM.  (2014)  Optimizing glucokinase activator binding kinetics to lower in vivo hypoglycemia risk,  (6): [10.1039/C4MD00027G]
10. Paczal A, Bálint B, Wéber C, Szabó ZB, Ondi L, Theret I, De Ceuninck F, Bernard C, Ktorza A, Perron-Sierra F, Kotschy A..  (2016)  Structure-Activity Relationship of Azaindole-Based Glucokinase Activators.,  59  (2): [PMID:26685731] [10.1021/acs.jmedchem.5b01594]
11. Fujieda H, Kogami M, Sakairi M, Kato N, Makino M, Takahashi N, Miyazawa T, Harada S, Yamashita T..  (2018)  Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus.,  156  [PMID:30006171] [10.1016/j.ejmech.2018.06.060]
12. Mollica L, Theret I, Antoine M, Perron-Sierra F, Charton Y, Fourquez JM, Wierzbicki M, Boutin JA, Ferry G, Decherchi S, Bottegoni G, Ducrot P, Cavalli A..  (2016)  Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times.,  59  (15): [PMID:27391254] [10.1021/acs.jmedchem.6b00632]